2-bromo-N,N-dioctylacetamide | 145570-18-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-bromo-N,N-dioctylacetamide
• 英文别名: Bromoacetamide, N,N-dioctyl-
• CAS: 145570-18-9
• 化学式: C₁₈H₃₆BrNO
• 分子量: 362.394
• InChiKey: XEFDAMQSIJLBRD-UHFFFAOYSA-N

物化性质

• 沸点：
  415.5±28.0 °C(Predicted)
• 密度：
  1.055±0.06 g/cm3(Predicted)
• 保留指数：
  2366

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  21
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-N,N-dioctylacetamide 在 氨 、 三乙胺 作用下， 生成 Acetamide, 2,2-Iminobis-
  参考文献：
  名称：

  Carriers for nucleotide 5'-triphosphate. 2. Liquid membrane and liposome transport

  摘要：

  We describe a series of new cationic carriers for the transport of nucleotide 5'-triphosphates across liquid organic membranes. The tetracationic compound 5, with two diquaternary 1,4-diaza[2.2.2]bicyclooctane (DABCO) units, forms carrier-nucleotide complexes of 1:1 stoichiometry in dichloromethane and strongly accelerates nucleotide transport across this solvent. As a result of a favorable balance of hydrophobicity and hydrophilicity, complexes of 5 do not leak out of the organic phase into the aqueous source or receiving phases. Liposome transport studies demonstrate that caution is strongly advised when extrapolating from liquid membrane studies to the transport across liposomes or cell membranes. The DABCO-based cationic carriers do not mediate specific nucleotide transport across the liposome walls but rather act as detergents to break the liposomal structure.

  DOI：

  10.1021/jo00054a021
• 作为产物：
  描述：

  二正辛胺 、 溴乙酰溴 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 以93%的产率得到2-bromo-N,N-dioctylacetamide
  参考文献：
  名称：

  Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapy

  摘要：

  该发明涉及至少包含一种脂质和至少一种有治疗活性的物质的复合物，用于将该物质转运到靶细胞中，其特征在于所述脂质的化学式为（I）：其中：n1、n2为0到1之间的整数；R1、R2相同或不同，选自由氢原子和烷基基团（含1到6个碳原子，可选地独立地被羟基基团取代）的群中；或在一个特定情况下，当n1=n2=1时，R1和R2可以共同形成2到3个碳原子（C2-C3）的二价烷基链；R3、R4相同或不同，为1到6个碳原子的烷基基团，或者共同形成2到3个碳原子（C2-C3）的二价烷基链；m、p相同或不同为1到10之间的整数；R5、R6相同或不同，选自下列基团的群中：1）R7C(═O)—X—其中：X=NH、O、S；R7为6到23个碳原子（C6-C23）的直链或支链烷基或烯基基团；2）R8R9NC(═O)—其中：R8、R9相同或不同，选自氢原子或6到23个碳原子的直链或支链烷基或烯基基团，前提是R8、R9不能同时对应于氢原子；3）并且其中一个基团R5、R6还可以对应于氢原子。该发明还涉及在基因治疗中使用所述复合物。

  公开号：

  US06291423B1

文献信息

• Liquid‐crystalline Metallomacrocycles Composed of Bis(hydroxypyridono)toluene Ligand and Cu ²⁺ Ions
  作者：Shin‐ichiro Kawano、Kohei Ideta、Tomohiko Banno、Kentaro Tanaka

  DOI：10.1002/asia.201901323

  日期：2019.12.2

  A series of π-extended chelating scaffolds incorporating two hydroxypyridone moieties were synthesized. X-ray crystallographic analysis revealed that a bis(hydroxypyridono)toluene ligand possessed a unique π-extended structure and exhibited efficient phase segregation from the aliphatic chains attached at the heterocyclic nitrogen. The bis-bidentate ligand formed a metal-coordination-induced macrocycle

  合成了一系列结合了两个羟基吡啶酮部分的π-延伸的螯合支架。X-射线晶体学分析表明，双（羟基吡啶酮）甲苯配体具有独特的π-延伸结构，并显示出与杂环氮上连接的脂族链有效的相分离。双齿双配体与Cu 2+离子形成金属配位诱导的大环。在络合过程中，在可见光区引起了光谱变化。此外，成功开发了具有适当侧链的金属大环液晶。通过金属介导的自组装形成的液晶大环的例子仍然很少。他们之中，
• Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy
  申请人：——

  公开号：US20020025920A1

  公开（公告）日：2002-02-28

  The present invention relates to a complex comprising at least a lipid and at least a therapeutically active substance for transferring the therapeutically active substance into a target cell. The present invention also relates to a method of transferring a therapeutically active substance into cells.

  本发明涉及至少包括脂质和至少一种治疗活性物质的复合物，用于将治疗活性物质转移至靶细胞。本发明还涉及将治疗活性物质转移至细胞的方法。
• THERAPEUTICS
  申请人：Potter Victor Lloyd Barry

  公开号：US20070105810A1

  公开（公告）日：2007-05-10

  The present invention relates to the use of a compound of formula (1): wherein: R1 comprises a carbonyl group and R2 is a hydrocarbyl group; optionally wherein said ring is further substituted; or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for use in one or more of: modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; modulating calcium spikes in mammalian cells; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes; treating diseases in one or more of brain, heart, pancreatic cells (e.g. pancreatic acinar and pancreatic beta cells), immune cells, T-cells, haemopoietic cells including phagocytes by modulating the release of intracellular calcium from a store controlled by nicotinic acid adenine dinucleotide phosphate; treating diseases in one or more of brain, heart, and T-cells by modulating calcium spikes in mammalian cells.

  本发明涉及使用式（1）的化合物或其药学上可接受的盐：其中R1包括一个羰基基团，R2是一个烃基团，可选择其中所述环进一步取代；用于制造药物，用于调节由烟酸腺嘌呤二核苷酸控制的储存内源性钙的释放；用于调节哺乳动物细胞中的钙峰；通过调节由烟酸腺嘌呤二核苷酸控制的储存内源性钙的释放，治疗脑部、心脏、胰腺细胞（例如胰腺导管细胞和胰岛β细胞）、免疫细胞、T细胞、包括吞噬细胞在内的造血细胞的疾病；通过调节哺乳动物细胞中的钙峰，治疗脑部、心脏和T细胞的疾病。
• Synthesis and lyotropic phase behavior of novel nonionic surfactants for the crystallization of integral membrane proteins
  作者：Jeffrey Walton、Gordon J.T. Tiddy、Simon J. Webb

  DOI：10.1016/j.tetlet.2005.11.103

  日期：2006.1

  A series of new sugar-based nonionic surfactants have been synthesized and their lyotropic liquid crystalline properties characterized. When in contact with water, these surfactants formed a range of lyotropic liquid crystalline phases, including cubic, hexagonal, and lamellar, as well as a separate micellar phase. These are features that have promise for the crystallization of integral membrane proteins. (c) 2005 Elsevier Ltd. All rights reserved.
• NOUVEAUX COMPLEXES LIPIDIQUES POUR LE TRANSFERT D'AU MOINS UNE SUBSTANCE THERAPEUTIQUEMENT ACTIVE, NOTAMMENT UN POLYNUCLEOTIDE, DANS UNE CELLULE CIBLE ET UTILISATION EN THERAPIE GENIQUE
  申请人：TRANSGENE S.A.

  公开号：EP0956050A1

  公开（公告）日：1999-11-17